Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Melanoma 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Renal Cell Carcinoma 1

Interventions

belinostat 2Nivolumab 2Ipilimumab 2Ifosfamide 2Filgrastim 2Doxorubicin 2spartalizumab 1balstilimab 1Specimen Handling 1Radiotherapy 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Fluorouracil 1Cyproheptadine 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × balstilimab × Genitourinary × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡